

Title (en)
STRATEGY FOR CARBOHYDRATE-BASED CANCER VACCINES

Title (de)
STRATEGIE FÜR KOHLENHYDRATEN IMPFSTOFFE GEGEN KREBS

Title (fr)
STRATEGIE POUR DES VACCINS THERAPEUTIQUES A BASE DE GLUCIDES

Publication
EP 1198244 A2 20020424 (EN)

Application
EP 00951149 A 20000728

Priority

- CA 0000886 W 20000728
- CA 2279134 A 19990729

Abstract (en)
[origin: WO0109298A2] The sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as alpha 2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express alpha 2-8 polysialic acid (i.e. various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified alpha 2-8 polysialic acid. The modification is suitably N-acylation of a precursor of the sialic acid, so that the N-acylated precursor becomes chemically incorporated in the polysialic acid during its intracellular biochemical synthesis. Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as alpha 2-8 polysialic acid) and a protein, can then be used to eliminate cells which express alpha 2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker, or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.

IPC 1-7
A61K 39/00; **A61K 39/385**; **C12N 5/08**; **C12N 5/06**; **A61P 35/00**

IPC 8 full level
C12N 5/07 (2010.01); **A61K 31/7008** (2006.01); **A61K 31/7012** (2006.01); **A61K 39/00** (2006.01); **A61K 39/095** (2006.01); **C12N 5/078** (2010.01); **C12N 5/09** (2010.01)

CPC (source: EP US)
A61K 31/7008 (2013.01 - EP); **A61K 31/7012** (2013.01 - EP); **A61K 39/001169** (2018.08 - EP US); **A61K 39/095** (2013.01 - EP); **A61P 35/00** (2018.01 - EP); **A61K 2039/5152** (2013.01 - EP US); **A61K 2039/6037** (2013.01 - EP)

Citation (examination)

- US 5102663 A 19920407 - LIVINGSTON PHILIP O [US], et al
- KAYSER H. ET AL, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 24, 25 August 1992 (1992-08-25), pages 16934 - 16938, XP000608481
- KEPPLER O.T. ET AL, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 3, 20 January 1995 (1995-01-20), pages 1308 - 1314

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0109298 A2 20010208; **WO 0109298 A3 20010823**; AU 6420000 A 20010219; CA 2279134 A1 20010129; EP 1198244 A2 20020424; IL 147776 A0 20020814; JP 2003506034 A 20030218; MX PA02000958 A 20030721; ZA 200200731 B 20030326

DOCDB simple family (application)
CA 0000886 W 20000728; AU 6420000 A 20000728; CA 2279134 A 19990729; EP 00951149 A 20000728; IL 14777600 A 20000728; JP 2001514090 A 20000728; MX PA02000958 A 20000728; ZA 200200731 A 20020128